---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000074"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:18:37.594125+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Autolus publishes UK Annual Report; provides obe-cel BLA status, PDUFA date Nov 16, 2024

## Summary
- BLA for obe-cel accepted by FDA; PDUFA target action date set for 16 November 2024.
- Phase 2 FELIX study data: 78% CR/CRi rate in evaluable r/r adult B-ALL patients; median follow-up 16.6 months.
- First two patients enrolled in CARLYSLE Phase 1 trial of obe-cel for SLE; initial data expected by end of 2024.
- In Phase 1 ALLCAR19 trial, 41% of patients in ongoing remission at 3-year median follow-up without transplant.
- AUTO1/22 dual-targeting CAR T showed 83% MRD-negative complete remission in paediatric r/r B-ALL.

## SEC filing metadata
- accession: 0001730463-24-000074
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000074/0001730463-24-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000074/autl-20240605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000074
- JSON: https://secwatch.observer/filing/0001730463-24-000074.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.